Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.72 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.72 |
| ▸ | CPT2 | P23786 | 1/20 | 0.72 |
| ▸ | ACLY | P53396 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 5/20 | 0.42 |
| ▸ | PPARD | Q03181 | 4/20 | 0.42 |
| ▸ | PPARA | Q07869 | 4/20 | 0.42 |
| ▸ | TERT | O14746 | 3/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | BLM | P54132 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | FABP4 | P15090 | 3/20 | 0.42 |
| ▸ | TOP1 | P11387 | 3/20 | 0.42 |
| ▸ | F7 | P08709 | 2/20 | 0.42 |
| ▸ | F3 | P13726 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5525620 | 1.00 | TDP1 (0.72) | TDP1FFAR1CPT2ACLYKDM4E | |
| SCHEMBL1834211 | 0.84 | FFAR1 (1.00) | TDP1FFAR1CPT2ACLYKDM4E | |
| SCHEMBL1832938 | 0.84 | FFAR1 (1.00) | TDP1FFAR1CPT2ACLYKDM4E | |
| SCHEMBL186164 | 0.84 | FFAR1 (1.00) | TDP1FFAR1CPT2ACLYKDM4E | |
| SCHEMBL5523390 | 0.84 | FFAR1 (1.00) | TDP1FFAR1CPT2ACLYKDM4E | |
| SCHEMBL8037883 | 0.84 | FFAR1 (1.00) | TDP1FFAR1CPT2ACLYKDM4E | |
| SCHEMBL29618243 | 0.79 | FFAR1 (0.65) | TDP1FFAR1CPT2ACLYKDM4E | |
| SCHEMBL8087636 | 0.78 | TDP1 (0.78) | TDP1FFAR1CPT2KDM4EPPARG | |
| SCHEMBL11104448 | 0.78 | FFAR1 (0.78) | TDP1FFAR1CPT2KDM4ECYP2C19 | |
| SCHEMBL5878804 | 0.77 | TDP1 (0.83) | TDP1FFAR1CPT2PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY (US) | 2007-08-30 | — | — | US | disclosed |
| EP-1572189-A1 | METHOD OF LOWERING CRP AND REDUCING SYSTEMIC INFLAMMATION | Warner-Lambert Company LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050026979-A1 | Methods for treating inflammation and inflammation-associated diseases with a statin and ether | GHAZZI MAHA (US) | 2005-02-03 | — | — | US | disclosed |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| US-20040167229-A1 | Method of lowering CRP and reducing systemic inflammation | BAKKER-ARKEMA REBECCA (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004045596-A1 | METHOD OF LOWERING CRP AND REDUCING SYSTEMIC INFLAMMATION | WARNER-LAMBERT COMPANY LLC (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | WARNER-LAMBERT COMPANY | 2004-03-11 | — | — | US | disclosed |
| US-4711896-A | ANTIDIABETIC, ANTILIPEMIC AGENTS | EPIS S.A. (CH) | 1987-12-08 | — | — | US | disclosed |
| EP-0185080-A1 | — | EPIS SA | 1986-06-25 | — | — | EP | disclosed |
| WO-1986000298-A1 | ALPHA-, OMEGA-DICARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION AND MEDICINES COMPOSED THEREOF | EPIS S.A. (CH) | 1986-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | TLR5, SSB, TLR4 | TDP1 2229/4885FFAR1 144/4885CPT2 360/4885 |
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | SYVN1, MMP13, TNF | TDP1 3613/4885FFAR1 1371/4885CPT2 714/4885 |
| US-20050026979-A1 | Methods for treating inflammation and inflammation-associated diseases with a statin and ether | HMGCR, CXCL8, DHCR7 | TDP1 3202/4885FFAR1 265/4885CPT2 434/4885 |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | PTGES2, PTGES, PTGER2 | TDP1 4216/4885FFAR1 449/4885CPT2 1268/4885 |
| US-20040167229-A1 | Method of lowering CRP and reducing systemic inflammation | ALB, TTR, IL6 | TDP1 3787/4885FFAR1 96/4885CPT2 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.